Lidbree

Lidocaine, the active ingredient in Lidbree, is a local anesthetic presented as a sterile intrauterine preparation for intrauterine use. It provides rapid onset of reversible nerve block, typically within minutes, and a duration of analgesia that supports pain‑free gynecologic procedures such as hysteroscopy, IUD insertion and endometrial biopsy in women.

GNH USA supplies Lidbree as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with reliable, on‑time delivery.

Lidbree, containing lidocaine, is employed for intrauterine anesthesia across several gynecologic procedures.

- Hysteroscopic surgery: provides analgesia to enable comfortable visualization and operative manipulation. - Intrauterine device (IUD) insertion: reduces insertion‑related pain and cramping. - Endometrial biopsy: numbs the uterine lining to minimize discomfort during tissue sampling.

Lidbree may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Uterine cramping: mild to moderate transient pain during or after administration. - Vaginal spotting or discharge: light bleeding for a short period. - Dizziness or light‑headedness: transient sensation of faintness. - Nausea: occasional mild stomach upset.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis requiring immediate medical attention. - Cardiovascular toxicity: arrhythmias, hypotension, or cardiac arrest in cases of systemic absorption. - Neurological events: seizures or central nervous system depression.

Prior to using Lidbree, clinicians should observe several precautionary measures to ensure patient safety.

- Allergy assessment: confirm no known hypersensitivity to lidocaine or related amide anesthetics. - Medical supervision: administer only by qualified healthcare professionals trained in intrauterine procedures. - Cardiovascular monitoring: observe heart rate and blood pressure during and after administration, especially in patients with cardiac disease. - Hepatic function: use caution in severe liver impairment, as lidocaine metabolism may be reduced. - Pregnancy considerations: evaluate risk‑benefit ratio before use in pregnant women, given limited data on intrauterine exposure. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lidocaine can interact with other medicines, altering its plasma concentration or increasing toxicity risk.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): may potentiate cardiac conduction effects and increase risk of arrhythmias. - Amiodarone: can markedly raise lidocaine levels, leading to systemic toxicity. - Cimetidine or other CYP3A4 inhibitors: may reduce lidocaine metabolism, increasing plasma concentrations.

Moderate Interactions (Monitor Closely): - Other local anesthetics: additive toxicity may occur if combined. - Beta‑blockers: may enhance lidocaine’s negative inotropic effects, requiring cardiac monitoring. - Diuretics (e.g., furosemide): may increase plasma lidocaine by reducing clearance.